Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
These men carry towers of birds through Mexico's streets. They say their tradition is dying out. - 2Here are 10 stores where you can get a free Thanksgiving turkey
- 3Raw oysters linked to ongoing salmonella outbreak infecting 64 across 22 states: CDC
- 4Bronze Age "City of Seven Ravines" unearthed in central Asia after 3,500 years
- 5Instructions to Back Your Sunlight powered chargers: Tracking down Possible Choices
- From Sea shores to Urban areas: Astonishing Worldwide Travel Objections
- Malaysia To Revive Search for Missing Flight MH370
- Interstellar comet 3I/ATLAS isn't an alien spacecraft, astronomers confirm. 'In the end, there were no surprises.'
- Islamic State group militants claim capture and execution of a Nigerian brigadier general
- The Beginning Of The End For Fossil Fuels Can Start In Colombia
- 6 Famous Urban communities for Shopping on the planet
- A Manual for Pick High Evaluated Food Conveyance Administrations In Significant Urban communities For 2024
- Moon-bound Artemis II astronauts enjoy a relaxed day in space
- November Lease Deals for the 2025 Kia EV6 are Too Good to Pass Up
